Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
02/05/2024 | Press release | Distributed by Public on 02/05/2024 11:10
Please select the service you want to use:
Smartlinks | Sodexo SA | Finance | Security Markets | Security Markets | Company News | Restaurants, Bars and Food Services | Travel, Leisure and Recreation Industry | Securities Issuers | Food Service Companies | London Stock Exchange (LSE) | Frankfurt Stock Exchange | Vienna Stock Exchange (ATX) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | OTC Markets | Tradegate Exchange | Euronext Paris | Cboe BXE Europe | Cboe CXE Europe | Cboe Off Exchange | Aquis Exchange | SIGMA X MTF | EuroTLX | Equiduct | Euronext Block MTF | Turquoise
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact